Long-Term Continuous Antimicrobial Resistance Surveillance Among Nosocomial Gram-Negative Bacilli in China from 2010 to 2018 (CMSS)

References

• Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1–55. doi:10.1111/1469-0691.12427
   PubMed Web of Science ®Google Scholar
• Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23:704–712. doi:10.1016/j.cmi.2017.09.00128893690
   PubMed Web of Science ®Google Scholar
• Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32:e00031–19.31462403
   PubMed Web of Science ®Google Scholar
• Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial stewardship: how the microbiology laboratory can right the ship. Clin Microbiol Rev. 2017;30:381–407. doi:10.1128/CMR.00066-1627974411
   PubMed Web of Science ®Google Scholar
• Wong D, Nielsen TB, Bonomo RA, et al. Clinical and pathophysiological overview of acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30:409–447.27974412
   PubMed Web of Science ®Google Scholar
• CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
   Google Scholar
• David S, Reuter S, Harris SR, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4:1919–1929. doi:10.1038/s41564-019-0492-831358985
   PubMed Web of Science ®Google Scholar
• Brolund A, Lagerqvist N, Byfors S, et al. Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveill. 2019;24:1900123. doi:10.2807/1560-7917.ES.2019.24.9.1900123
   Google Scholar
• Jones RN, Mendes C, Turner PJ, et al. An overview of the meropenem yearly susceptibility test information collection (MYSTIC) program: 1997–2004. Diagn Microbiol Infect Dis. 2005;53:247–256. doi:10.1016/j.diagmicrobio.2005.10.00616360548
   PubMed Web of Science ®Google Scholar
• Masterton RG, Kuti JL, Turner PJ, et al. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother. 2005;55:71–77. doi:10.1093/jac/dkh51115574471
   PubMed Web of Science ®Google Scholar
• Korten V, Ulusoy S, Zarakolu P, et al. Antibiotic resistance surveillance over a 4-year period (2000–2003) in Turkey: results of the MYSTIC program. Diagn Microbiol Infect Dis. 2007;59:453–457. doi:10.1016/j.diagmicrobio.2007.06.01617888609
   PubMed Web of Science ®Google Scholar
• Rhomberg PR, Deshpande LM, Kirby JT, et al. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC program (2006). Diagn Microbiol Infect Dis. 2007;59:425–432. doi:10.1016/j.diagmicrobio.2007.05.00917662557
   PubMed Web of Science ®Google Scholar
• Wang H, Chen M, Ni Y, et al. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003–2008. Int J Antimicrob Agents. 2010;35:227–234. doi:10.1016/j.ijantimicag.2009.11.01020047820
   PubMed Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100 Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. 2020 Available from: http://www.eucast.org.
   Google Scholar
• Yang Q, Wang H, Sun H, et al. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob Agents Chemother. 2010;54:573–577. doi:10.1128/AAC.01099-0919805565
   PubMed Web of Science ®Google Scholar
• Wang X, Xu X, Li Z, et al. An outbreak of a nosocomial NDM-1-producing Klebsiella pneumoniae ST147 at a teaching hospital in mainland China. Microb Drug Resist. 2014;20:144–149. doi:10.1089/mdr.2013.010024199986
   PubMed Web of Science ®Google Scholar
• Delattre IK, Taccone FS, Jacobs F, et al. Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther. 2017;15:677–688. doi:10.1080/14787210.2017.133813928571493
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31.
   Web of Science ®Google Scholar
• Bulik CC, Bader JC, Zhang L, et al. PK-PD compass: bringing infectious diseases pharmacometrics to the patient’s bedside. J Pharmacokinet Pharmacodyn. 2017;44:161–177. doi:10.1007/s10928-017-9518-028353185
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004;189:1590–1597. doi:10.1086/38332015116294
   PubMed Web of Science ®Google Scholar
• Preston SL, Drusano GL, Berman AL, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998;42:1098–1104. doi:10.1128/AAC.42.5.10989593134
   PubMed Web of Science ®Google Scholar
• China Antimicrobial Resistance Surveillance System. China antimicrobial resistance surveillance report, 2018  Available from: http://carss.cn/Report/Details/648. Accessed July 23, 2020.
   Google Scholar
• Wang X, Wang Q, Cao B, et al. Impact of combination therapy vs monotherapy on mortality from carbapenem-resistant Enterobacteriaceae bacteremia: a retrospective observational study from a Chinese network. Antimicrob Agents Chemother. 2018. doi:10.1128/AAC.01511-18
   Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682–707. doi:10.1128/CMR.05035-1123034326
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network. Antimicrob Agents Chemother. 2018;62.
   Web of Science ®Google Scholar
• Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis. 2018;67:S196–S205. doi:10.1093/cid/ciy66030423057
   PubMed Web of Science ®Google Scholar
• Li H, Zhang J, Liu Y, et al. Molecular characteristics of carbapenemase-producing Enterobacteriaceae in China from 2008 to 2011: predominance of KPC-2 enzyme. Diagn Microbiol Infect Dis. 2014;78:63–65. doi:10.1016/j.diagmicrobio.2013.10.00224211218
   PubMed Web of Science ®Google Scholar
• Ruppe E, Olearo F, Pires D, et al. Clonal or not clonal? Investigating hospital outbreaks of KPC-producing Klebsiella pneumoniae with whole-genome sequencing. Clin Microbiol Infect. 2017;23(7):470–475. doi:10.1016/j.cmi.2017.01.01528143787
   PubMed Web of Science ®Google Scholar
• Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med. 2012;4:148ra16–ra16. doi:10.1126/scitranslmed.3004129
   Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Ikawa K, et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56:272–282. doi:10.1093/cid/cis85723074314
   PubMed Web of Science ®Google Scholar
• Guan X, He L, Hu B, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22(Suppl 1):S15–25. doi:10.1016/j.cmi.2015.11.00426627340
   PubMed Web of Science ®Google Scholar
• Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22:S9–14. doi:10.1016/j.cmi.2016.01.00127000156
   PubMed Web of Science ®Google Scholar